Particolarità molecolari delle neoplasie sarcomatose: Quale lezione biologica possiamo trarre per tutte le altre neoplasie?
|
|
- Willis Morris
- 5 years ago
- Views:
Transcription
1 Particolarità molecolari delle neoplasie sarcomatose: Quale lezione biologica possiamo trarre per tutte le altre neoplasie? Bruno Vincenzi, MD PhD Università Campus Bio-Medico di Roma
2 Defining sarcoma Rare tumors (less than case in U.S.A in 2012) Clinical heterogeneity (good vs. very dismal prognosis) Histologic heterogeneity (~ 70 STSs) Molecular heterogeneity
3 Defining sarcoma: role of molecular heterogenety DISEASE CHROMOSOMAL CHANGE FUSION GENE FREQ Ewing s, PNET t(11;22) or t(21;22) EWS-FLI1, EWS RG 95% Synovial sarcoma t(x;18) SYT-SSX 95% Myxoid liposarcoma t(12;16) CHOP-TLS 80% Clear cell sarcoma t(12;22) EWS-ATF % DIAGNOSIS THERAPY Desmoplastic SRCT t(11;22)(p13;q12) EWS-WT1 > 50% Alveolar rhabdomyosarcoma t(2;13) PAX-3-FKHR 70% Alveolar rhabdomyosarcoma t(1;13) PAX-7-FKHR 20% Osteosarcoma 1p-, 6q-,9p-, 13q-, 3q-, others NA Myxoid chondrosarcoma t(9;22) 50-70% PROGNOSIS Dermatofibrosarcoma t(17;22), ring chrom. COL1A1-PDGF >50%
4 STS STS with tumor-specific genetic alterations e.g. fusion genes involving EWSR1 ESFT FLI1 ETV1 ETV4 FEV ERG EWSR1 WT1 Desmoplastic Small Round Cell Tumor ZSG CREB1 ATF1 Clear Cell Sarcoma and Angiomatoid Fibrous Hystiocitoma
5 Defining sarcoma: role of molecular heterogenety FOUR GROUP OF SARCOMA
6 Defining sarcoma: role of molecular heterogenety GROUP 1 Nonpleomorphic histology Known pathognomonic molecular events (eg, GIST, DFSP) GROUP 2 Younger patients Nonpleomorphic histology Karyotypes of limited complexity Pathognomonic molecular events, which are likely to exist, have yet to be identified (eg, chordoma)
7 Defining sarcoma: role of molecular heterogenety GROUP 3 Adult Pleomorphic histology Identified molecular events (eg, DDLPS) GROUP 4 Adult Complex karyotypes pleomorphic histology No identifiable molecular events (eg, pleom. sarcoma)
8 Traslating molecular heterogenity into diagnostic tools TRASLOCATIONS REARRANGEMENTS RING CHROMOSOMES AMPLIFICATIONS Inflammatory myofibroblastic tumour Dermatofibrosarcoma protuberans WDLPS/DDLPD 2p23 rearrangement Ring Chromosome 17 and 22 t(17;22) (q21;q13) Supernumerary ring and gigant chromosome ALK activation COL1A1 PDGFB fusion COL1A1 PDGFB fusion MDM2 amplification
9 Target therapy for sarcoma DFSP COL1A1-PDGFB1 fusion gene IMATINIB Myxoid Lyposarcoma TLS-CHOP fusion gene TRABECTEDIN TGCT COL6A3-CSF1 fusion gene IMATINIB GIST KIT and PDGFRa activating mutations IMATINIB, SUNITINIB
10 Target therapy for GIST:imatinib 90% KIT acitivating mutations 6-8% PDGFRA acitivating mutations Imatinib at 400 mg daily 5-10% GIST WT Exon 11 KIT mutations PR was 83.5%, exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P.0006) and 0.0% (P<.0001), respectively. Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation. Heinrich MC. et al. J Clin Oncol. 2003; 21:
11 Target therapy for GIST: role of mutational analysis CONCLUSION: The clinical activity of sunitinib after imatinib failure is significantly influenced by both primary and secondary mutations in the predominant pathogenic kinases, which has implications for optimization of the treatment of patients with GIST.
12 Target therapy for DFSP Imatinib at 400 mg twice daily Locally advanced or metastatic DFSP t(17;22)
13 Target therapy for myxoid liposarcoma t(12;16), t (12;22) TLS-CHOP fusion, EWS- CHOP fusion Binding to C/EBP α E C/EBP β promoters Arrest of lipoblast differentiation ET-743 promotes lipoblast differentiation reducing FUS-CHOP or EWS-CHOP expression
14 Target therapy for myxoid liposarcoma Trabectedin is Cytotoxic for Monocytes and TAMs % OF VIABLE CELLS * * IC 50 on tumour cells Taxol Cisplatin Doxorubicin % OF VIABLE CELLS % OF VIABLE CELLS * * * % OF VIABLE CELLS Drug concentrations Allavena P, et al. Cancer Res
15 Target therapy for myxoid liposarcoma CCL2 * * ** Ctrl IL-6 * ** Ctrl VEGF * ** Ctrl Ang2 * ** Ctrl TNF Ctrl Trabectedin selectively reduces some inflammatory cytokines in monocytes and macrophages at infra-cytotoxic levels Allavena P, et al. Cancer Res and 2010.
16 Sarcoma translational research: the near future Clinical efficacy of sunitinib in ASPS, mediated by PDGFRB, VEGFR2, and RET, which are all expressed in tumor cells.
17 Sarcoma translational research: the near future Clinical benefits 70 % of SD 20% OF PR 1 PD
18 Sarcoma translational research: the near future CASE REPORT PATIENT 1 (Rearrangements involving the ALK locus on chromosome 2p23) 13 weeks of treatment with crizotinib PR PATIENT 2( No AKL rearrangement) PD after 8 weeks
19 Sarcoma translational research: the near future 2011: Insulin-like growth factor signalling for sarcoma subtypes, including Ewing s sarcoma ANTI- IGF-1R: FIGITUMUMAB
20 Sarcoma translational research: the near future Phase l trial in patients with soft-tissue sarcoma (STS) including Ewing s sarcoma enrolled 24 patients, 16 with Ewing s sarcoma PRIMARY END POINT Safety and tolerability of figitumumab. SECONDARY END POINT Pharmacokinetic profiling and preliminary antitumour activity (according to RECIST criteria)
21 Sarcoma translational research: the near future Figitumumab is well tolerated and has antitumour activity in Ewing s sarcoma Objective response in 2 cases SD in 8 patients
22 Sarcoma translational research: the near future VEGFR overespressed Primary End point PFS at 9 months according to RECIST criteria Sorafenib did not reach the predefined level of activity and provided stable disease of limited duration for patients with advanced and pretreated angiosarcoma.
23 Sarcoma translational research: the near future pivotal phase III trial in patients with metastatic soft-tissue sarcoma (STS) NO GIST or adypocytic sarcomas whose disease has progressed during or following prior chemotherapy randomized, double-blind, placebo-controlled enrolled 369 patients
24 Sarcoma translational research: the near future PRIMARY END POINT progression-free survival (PFS) These PFS benefits were consistently seen across a lot of patient subgroups based on STS histology, including leiomyosarcoma, synovial sarcoma, and other types of sarcoma
25 Sarcoma translational research: the near future IGF R1 Figitumumab IGF R1 P13K/AKT/mTOR ANGIOGENESIS Deferolimus, Everolimus Bevacizumab Sunitinib Sorafenib Pazopanib mtor VEGF a VEGFR 1/ 2/ 3; PGFR; KIT; FLT3; RET; CSF 1 RAF1, VEGFR 1/ 2/ 3 PDGFR, VEGFR, c kit
26 Sarcoma translational research: the near future RIDAFOROLIMUS PI3K TSC PTEN PI3K AKT mtor mtor signaling dysregulated in multiple sarcomas ridaforolimus is a rapamycin analog and potent mtor inhibitor FKBP Ridaforolimus 4E-BP1 clinical activity in sarcomas in phase I and II studies
27 Sarcoma translational research: the near future pivotal phase III trial in patients with metastatic disease who have had a favorable outcome to chemotherapy 1. patients with ongoing CR, PR, or SD following prior therapy 2. disease status confirmed through independent radiographic review prior to randomization randomized, double-blinded, placebo-controlled trial 1:1 randomization, oral ridaforolimus vs placebo enrolling approximately 650 patients 13 years of age multicenter trial: approximately 150 centers worldwide
28 Sarcoma translational research: the near future PRIMARY ENDPOINT progression-free survival (PFS) SECONDARY ENDPOINTS overall survival (OS) best target lesion response improvement in cancer-related symptoms safety and tolerability CAMBRIDGE, Mass., Jan 18, 2011 ARIAD Announces Oral Ridaforolimus Achieved Primary Endpoint of Improved Progression- Free Survival in Patients with Metastatic Soft-Tissue or Bone Sarcomas in the Phase 3 SUCCEED Trial
29 Sarcoma biomarkers for prognosis and therapy: future perspective mirna Cytokines Vascular spread biomarkers CTC
30 Sarcoma biomarkers for prognosis and therapy: future perspective D-dimer levels as possible marker of tumor progression and prognosis in musculoskeletal sarcoma ( Sleeman et al., 2011) VEGF-CmRNA and VEGF-C protein relative as biomarkers of lympahtic metastasis (Pollock et al., 2010) NOTCH pathway probabily acts in metastatic spread in osteosacroma (Bray SJ et al.,2006)
31 Sarcoma biomarkers for prognosis and therapy: future perspective Upregulation of mir-21 in osteosarcomas increcreased cell invasion and migration (Lulla RR et al., 2011) Downregulation of mir155 causes growth arrest in DDLPS (Zhang, P. et al.2012) Mir125 a is upregulated in SS causing cell proliferation (Hisaoka, M. et al., 2011)
32 Sarcoma biomarkers for prognosis and therapy: future perspective Circulating tumor cells Ewing s sarcoma CTCs/DTCs are strong predictor of recurrent disease in patients with Ewing family tumors (Avigad et al,. 2004) excellent prognosis in a subset of patients with ES + CD56 positive DTCs (Ash et al,., 2011)
33 Sarcoma biomarkers for prognosis and therapy: future perspective Circulating tumor cells Osteosarcoma CTCs specific mrnas correlate with dismal prognosis and metastases risk (Wong IH,2000) DTCs are very common in osteosarcoma patients and correlate with dismal prognosis (Bruland et al., 2005)
34 Conclusion Rare tumors Molecular hetorogenty is a useful tool togheter histology for: - Diagnosis -Therapy - Prognosis Thus, the biology of sarcomas suggests that they can represent a paradigm among solid tumors for the translation of gene expression into clinical care.
Klinisch belang van chromosomale translocatie detectie in sarcomen
Translocations in sarcomas Klinisch belang van chromosomale translocatie detectie in sarcomen Judith V.M.G. Bovée, M.D., Ph.D. Department of Pathology Leiden University Medical Center RNA binding DNA binding
More informationCurrent and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
More informationHistotype or molecular driven treatment of sarcomas?
Histotype or molecular driven treatment of sarcomas? Prof.ssa Maria A Pantaleo Dipartimento Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna GistStudyGroup Sarcomastudygroup Bologna
More informationMolecular pathology in soft tissue tumors. Sylvia Höller Pathologie
Molecular pathology in soft tissue tumors Sylvia Höller Pathologie When do we perform molecular testing? Morphology and IHC are not clearly fitting with an entity some translocations are entity specific
More informationBest of ASCO 2014 Sarcoma
Best of ASCO 2014 Sarcoma Robin L Jones Seattle Cancer Care Alliance University of Washington Fred Hutchinson Cancer Research Center Presentation Outline Overview progress made in sarcoma Highlight 2 trials
More informationManaging adult soft tissue sarcomas and gastrointestinal stromal tumours
Managing adult soft tissue sarcomas and gastrointestinal stromal tumours Sarcomas and gastrointestinal stromal tumours include a wide variety of biologically diverse cancers, many of them very rare. Paolo
More informationMolecular pathology/genetics of sarcomas
Molecular pathology/genetics of sarcomas Gunhild Mechtersheimer Institute of Pathology, University of Heidelberg Sarkomkonferenz: 17.03.2011 Berlin Characterization of soft tissue sarcomas / STS (~ 1%
More informationDisclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
More informationPredictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities
Predictive biomarker profiling of > 1,900 sarcomas: Identification of potential novel treatment modalities Sujana Movva 1, Wenhsiang Wen 2, Wangjuh Chen 2, Sherri Z. Millis 2, Margaret von Mehren 1, Zoran
More informationSarcomas. Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center
Sarcomas Living Beyond Cancer A-Z UT Health San Antonio MD Anderson Cancer Center Aaron Sugalski, DO Associate Professor of Pediatric Hematology/Oncology Medical Director, UHS Pediatric Blood and Cancer
More informationTrabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract
Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,
More informationI sarcomi dei tessuti molli
Novità e sequenze terapeutiche nelle neoplasie ginecologiche, melanoma e tumori rari: I sarcomi dei tessuti molli Giacomo G. Baldi Oncologia Medica Sandro Pitigliani Nuovo Ospedale S.Stefano Azienda USL
More informationRare Cancers. Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Sarcoma Patient Symposium October 15, 2017
Rare Cancers Andrew J. Wagner, MD, PhD Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Sarcoma Patient Symposium October 15, 2017 Why should we care about Rare Cancers? Raise your hand
More informationTherapeutic Algorithms in systemic sarcoma therapy
Therapeutic Algorithms in systemic sarcoma therapy Ian Judson Sarcoma Unit Royal Marsden Hospital What evidence do we have? What sorts of evidence are there? Experience personal, peers ( Bayesian ) Educational
More informationA PHASE 1B DOSE-ESCALATION STUDY OF TRC105 (ANTI-ENDOGLIN ANTIBODY) IN COMBINATION WITH PAZOPANIB IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS)
A PHASE 1B DOSE-ESCALATION STUDY OF TRC105 (ANTI-ENDOGLIN ANTIBODY) IN COMBINATION WITH PAZOPANIB IN PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) S. Attia 1, R.F. Riedel 2, S.I. Robinson 3, R.M. Conry
More informationDisclosures. An update on ancillary techniques in the diagnosis of soft tissue tumors. Ancillary techniques. Introduction
Disclosures An update on ancillary techniques in the diagnosis of soft tissue tumors. I have nothing to disclose. Andrew Horvai, MD, PhD Clinical Professor, Pathology Introduction Ancillary techniques
More informationHOW MAY THE CLASSIFICATION OF SOFT TISSUE TUMORS EVOLVE?
Spanish Society of Pathology Zaragoza, May 2011 ARTHUR PURDY STOUT SYMPOSIUM HOW MAY THE CLASSIFICATION OF SOFT TISSUE TUMORS EVOLVE? Christopher D.M. Fletcher, M.D., FRCPath Brigham and Women s Hospital
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationTumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia
Tumores de células pequeñas, redondas y azules: diagnóstico diferencial cuando el tiempo apremia Sílvia Bagué Servei de Patologia Hospital de Sant Pau Barcelona Soft tissue sarcomas Heterogeneous group
More informationLa chemioterapia neoadiuvante nei sarcomi: novità e attuali indicazioni Lorenzo D Ambrosio, MD PhD Divisione di Oncologia Medica Istituto di Candiolo
La chemioterapia neoadiuvante nei sarcomi: novità e attuali indicazioni Lorenzo D Ambrosio, MD PhD Divisione di Oncologia Medica Istituto di Candiolo Fondazione del Piemonte per l Oncologia. IRCCS 12 CONGRESSO
More informationPerspectives in 2 nd line treatment of advanced Soft tissue Sarcoma treatment approaches. Dr.Dana Stănculeanu Bucharest Institute of Oncology
Perspectives in 2 nd line treatment of advanced Soft tissue Sarcoma treatment approaches Dr.Dana Stănculeanu Bucharest Institute of Oncology Epidemiology of soft tissue sarcoma STS accounts for
More informationPROBLEMS OF PROGNOSTICATION IN SOFT TISSUE TUMOURS. Christopher D.M. Fletcher Brigham and Women s Hospital and Harvard Medical School Boston, MA
PROBLEMS OF PROGNOSTICATION IN SOFT TISSUE TUMOURS Christopher D.M. Fletcher Brigham and Women s Hospital and Harvard Medical School Boston, MA Dr. Fletcher has no conflict of interest or disclosures to
More informationConceptual Evolution of Soft Tissue Tumors Classification
Conceptual Evolution of Soft Tissue Tumors Classification Angelo P. Dei Tos M.D. Departments of Pathology & Oncology Treviso, Italy How WHO classification was reshaped Pathologists and Cytogeneticists
More informationThe new Leeds Solid Tumour Molecular Oncology Diagnostics Service. Paul Roberts, Genetics, Leeds
The new Leeds Solid Tumour Molecular Oncology Diagnostics Service Paul Roberts, Genetics, Leeds Molecular Oncology services pre-2013 DNA lab Germline cancer Cytogenetics lab FISH, cell culture, molecular
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationComprehensive Sarcoma Genomic Profiling, in record time. Accurate. Clinically Proven. Fast.
Comprehensive Sarcoma Genomic Profiling, in record time Accurate. Clinically Proven. Fast. Morphologic diagnosis based on microscopic examination of histologic sections remains the gold standard for sarcoma
More informationAdvances in sarcoma diagnostics and treatment
/, 2017, Vol. 8, (No. 4), pp: 7068-7093 Advances in sarcoma diagnostics and treatment Review Amanda R. Dancsok 1, Karama Asleh-Aburaya 1 and Torsten O. Nielsen 1,2 1 Pathology and Laboratory Medicine,
More informationFinancial disclosures
An update on immunohistochemical markers in mesenchymal neoplasms By Konstantinos Linos MD, FCAP, FASDP Assistant Professor of Pathology Geisel School of Medicine at Dartmouth Dartmouth-Hitchcock Medical
More informationUpdate on Sarcomas of the Head and Neck. Kevin Harrington
Update on Sarcomas of the Head and Neck Kevin Harrington Overview Classification and incidence of sarcomas Clinical presentation Challenges to treatment Management approaches Prognostic factors Radiation-induced
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationOverview of New Drugs for GIST following resistance to standard TKIs (imatinib and sunitinib)
Overview of New Drugs for GIST following resistance to standard TKIs (imatinib and sunitinib) George D. Demetri, M.D. Center for Sarcoma and Bone Oncology Dana-Farber Cancer Institute Harvard Medical School
More informationMolecular Genetics of Paediatric Tumours. Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA
Molecular Genetics of Paediatric Tumours Gino Somers MBBS, BMedSci, PhD, FRCPA Pathologist-in-Chief Hospital for Sick Children, Toronto, ON, CANADA Financial Disclosure NanoString - conference costs for
More informationFluorescence In Situ Hybridization in the Diagnosis of Soft Tissue Neoplasms: A Review. Munir R. Tanas, MD and John R.
REVIEW ARTICLE Fluorescence In Situ Hybridization in the Diagnosis of Soft Tissue Neoplasms: A Review Munir R. Tanas, MD and John R. Goldblum, MD Abstract: This paper presents an overview of the role of
More informationContents Part I Introduction 1 General Description 2 Natural History: Importance of Size, Site, Histopathology
Contents Part I Introduction 1 General Description... 3 1.1 Introduction... 3 1.2 Incidence and Prevalence... 5 1.3 Predisposing and Genetic Factors... 8 References... 16 2 Natural History: Importance
More informationIntroduction to Musculoskeletal Tumors. James C. Wittig, MD Orthopedic Oncologist Sarcoma Surgeon
Introduction to Musculoskeletal Tumors James C. Wittig, MD Orthopedic Oncologist Sarcoma Surgeon www.tumorsurgery.org Definitions Primary Bone / Soft tissue tumors Mesenchymally derived tumors (Mesodermal)
More informationJon Trent, MD, PhD. Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
Gastrointestinal Stromal Tumor GISTS 2010: After Standard of Care Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center jtrent@mdanderson.org
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationIan Judson and Winette T. van der Graaf
SARCOMA Olaratumab really a breakthrough for soft-tissue sarcomas? Ian Judson and Winette T. van der Graaf In a recent study, the addition of olaratumab to doxorubicin chemotherapy for patients with soft-tissue
More informationDisclosure of Relevant Financial Relationships
Ewing and Ewing like sarcomas Using Genetic Signatures in Refining Small Blue Round Cell Tumor Classification Cristina Antonescu, MD Department of Pathology Disclosure of Relevant Financial Relationships
More informationCutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchcock Medical Center
More information17/01/2017. Use of kinase inhibitors in oncology practice. Multikinase inhibitors. Sunitinib (Sutent )targets. Many more sunitinib kinase targets (42)
Multikinase inhibitors Use of kinase inhibitors in oncology practice Prof Jacques De Grève, UZ Brussel Inhibit multiple intracellular and cell surface kinases Tyrosine or serine-threonine kinases Multitargeting
More informationDevelopment of New Treatment Modalities Oncolytic Viruses and Nanotechnique
Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique By Professor Kjell Öberg, M.D., Ph.D. Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden Nashville Oct. 2011 Hallmarks
More informationÉpidémiologie des sarcomes en Belgique
1 Épidémiologie des sarcomes en Belgique Dr. Liesbet Van Eycken 12 es journées annuelles du GSF-GETO Oud Sint-Jan Bruges, 22-24 juin 2016 Overview Introduction Descriptive epidemiology Incidence Age specific
More informationUpdate on Cutaneous Mesenchymal Tumors. Thomas Brenn
Update on Cutaneous Mesenchymal Tumors Thomas Brenn Cutaneous Mesenchymal Tumours Wide morphological and biological spectrum Myofibroblastic, smooth muscle, neural, vascular, apidocytic, undifferentiated;
More informationKEY ADVANCES IN THE SYSTEMIC THERAPY FOR SOFT TISSUE SARCOMAS: CURRENT STATUS AND FUTURE DIRECTIONS
KEY ADVANCES IN THE SYSTEMIC THERAPY FOR SOFT TISSUE SARCOMAS: CURRENT STATUS AND FUTURE DIRECTIONS Neelesh Soman, 1 James Hu, 2 Vivek Subbiah, 3 and Sant Chawla 1 1. Sarcoma Oncology Center, Santa Monica,
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationSequencing of therapies in mrcc. Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC
Sequencing of therapies in mrcc Ari Hakimi MD Assistant Professor Urology Service, Department of Surgery MSKCC Old Paradigm Sequencing approved agents VEGF TKI Sunitinib Pazopanib Axitinib TKI TKI MTORi
More informationCombining Targeted Agents With Modern Radiotherapy in Soft Tissue Sarcomas
DOI:10.1093/jnci/dju329 First published online October 18, 2014 The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
More informationMolecular Diagnosis of Soft Tissue Tumors: Avoid Pitfalls
Molecular Diagnosis of Soft Tissue Tumors: Avoid Pitfalls Cristina Antonescu, MD Department of Pathology Memorial Sloan-Kettering Cancer Center, New York Overview I. When should we rely on the help of
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationOncology Cytogenetics Diagnostic Service - User Guide 2014
Oncology Cytogenetics Diagnostic Service - User Guide 2014 Contact details Address: Cytogenetics Department 5 th Floor Tower Wing Guy s Hospital Great Maze Pond London SE1 9RT General enquiries 0207 188
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationGene Translocations in Musculoskeletal Neoplasms
Clin Orthop Relat Res (2008) 466:2131 2146 DOI 10.1007/s11999-008-0342-0 SYMPOSIUM: MOLECULAR GENETICS IN SARCOMA Gene Translocations in Musculoskeletal Neoplasms Balaji Krishnan MS, Gaurav Khanna MD,
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationCarcinoma de Tiroide: Teràpies Diana
Carcinoma de Tiroide: Teràpies Diana Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology THYROID CANCER:
More informationNovel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
More informationASCP Resident Review Mini-Course Series Session 2: Renal and Soft Tissue Pathology. Carole Vogler MD, FASCP Ema Dragoescu MD
178 2011 ASCP Resident Review Mini-Course Series Session 2: Renal and Soft Tissue Pathology Carole Vogler MD, FASCP Ema Dragoescu MD 2011 Annual Meeting Las Vegas, NV AMERICAN SOCIETY FOR CLINICAL PATHOLOGY
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationUNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationRegorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted
More informationSystemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.
Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Arturo Loaiza-Bonilla, MD, FACP Assistant Professor of Clinical Medicine
More informationTrabectedina + PLD nel trattamento del carcinoma ovarico. Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano
Trabectedina + PLD nel trattamento del carcinoma ovarico Nicoletta Colombo Universita Milano Bicocca Istituto Europeo Oncologia Milano The old definition of Recurrent Ovarian Cancer P R I M A R Y T H E
More informationReview Article Targeted Therapies in Sarcomas: Challenging the Challenge
Sarcoma Volume 2012, Article ID 626094, 13 pages doi:10.1155/2012/626094 Review Article Targeted Therapies in Sarcomas: Challenging the Challenge Juan Martín Liberal, 1 Laura Lagares-Tena, 1 Miguel Sáinz-Jaspeado,
More informationINDEX. in this web service Cambridge University Press
actin 14 adamantinoma 202, 290 292, 297 adenocarcinoma 136 adipocytes in hibernoma 149, 150 in lipoblastoma 148 in lipoma 141, 142, 145 in liposarcoma 152 in myelolipoma 151 adrenal gland tumors see myelolipoma
More informationClinical Trials. Phase II Studies. Connective Tissue Oncology Society. Jon Trent, MD, PhD
Clinical Trials Phase II Studies Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center Connective Tissue Oncology Society GIST Overview
More informationResponse and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
More informationNew Treatment Strategies in Osteosarcoma. PD Dr. Claudia Blattmann, Prof. Dr. Stefan Bielack Olgahospital Klinikum Stuttgart Germany
New Treatment Strategies in Osteosarcoma PD Dr. Claudia Blattmann, Prof. Dr. Stefan Bielack Olgahospital Klinikum Stuttgart Germany Introduction Most common bone tumor in children, adolescents and young
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More informationReview Article Molecular classification of soft tissue sarcomas and its clinical applications
Int J Clin Exp Pathol 2010;3(4):416-429 www.ijcep.com /IJCEP1003008 Review Article Molecular classification of soft tissue sarcomas and its clinical applications Shilpa Jain 1, Ruliang Xu 1, Victor G.
More informationJournal of Solid Tumors, April 2012, Vol. 2, No. 2
ORIGINAL ARTICLE Utility of fluorescence in situ hybridization in subclassifying unclassified high-grade sarcomas: A study of 40 cases using break-apart probes of EWSR1, FOXO1A, SS18 and DDIT3 genes Alfredo
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationBreast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2 on all newly diagnosed cases
Adrenal cortical carcinoma Inhibin Synap Melan-A Calretinin Vimentin Chromogr CK7 CK20 Breast - ductal carcinoma CK7 ER PR GATA3 Mammaglobin (50-70%) GCDFP-15 (50-70%) E-cadherin HMWCK CK20 PAX2 ER/PR/HER2
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationPathology Mystery and Surprise
Pathology Mystery and Surprise Tim Smith, MD Director Anatomic Pathology Medical University of South Carolina Disclosures No conflicts to declare Some problem cases Kidney tumor Scalp tumor Bladder tumor
More informationSORAFENIB BLOCKS TUMOUR GROWTH, ANGIOGENESIS AND METASTATIC POTENTIAL IN PRECLINICAL MODELS OF OSTEOSARCOMA
SORAFENIB BLOCKS TUMOUR GROWTH, ANGIOGENESIS AND METASTATIC POTENTIAL IN PRECLINICAL MODELS OF OSTEOSARCOMA Ymera Pignochino, PhD Division of Medical Oncology IRCC - Candiolo - TO CLINICAL FEATURES OF
More informationFinancial disclosures
Cutaneous Mesenchymal Neoplasms with EWSR1 Rearrangement By Konstantinos Linos MD, FCAP, FASDP Bone, Soft Tissue and Dermatopathology Assistant Professor of Pathology Dartmouth-Hitchc Geisel School of
More informationRecent Advances In Select Round Cell Sarcomas
Recent Advances In Select Round Cell Sarcomas Rajiv M. Patel, M.D. Associate Professor of Pathology & Dermatology University of Michigan, Ann Arbor, MI rajivpat@med.umich.edu 1 Translocation Associated
More information5/10. Pathology Soft tissue tumors. Farah Bhani. Mohammed Alorjani
5/10 Pathology Soft tissue tumors Mohammed Alorjani Farah Bhani Slides are included in this sheet. Objectives: Soft tissue tumors 1. Describe soft tissue tumors. 2. Understand the classification of soft
More informationScientific Perspectives of Olaratumab Beyond the Approval Indication
Scientific Perspectives of Olaratumab Beyond the Approval Indication William D. Tap, MD Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center GEIS XVI International Symposium October
More informationImmunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD
Immunohistochemistry in Bone and Soft Tissue Tumors Sahar Rassi Zankoul, MD Introduction Bone tumors represent a wide variety of tumors of various origins and malignant potentials. These different tumor
More informationLong Term Results in GIST Treatment
Long Term Results in GIST Treatment Dr. Laurentia Gales Prof. Dr. Rodica Anghel, Dr. Xenia Bacinschi Institute of Oncology Prof Dr Al Trestioreanu Bucharest 25 th RSRMO October 15-17 Sibiu Background Gastrointestinal
More informationOMONDI OGUDE MEDICAL ONCOLOGY
OMONDI OGUDE MEDICAL ONCOLOGY Personalized medicine (Targeted therapy) In recent years there s been a move from conventional cytotoxic therapy to more targeted therapy Mostly due to the rapid pace of
More informationShintaro Sugita *, Hiroko Asanuma and Tadashi Hasegawa
Sugita et al. Diagnostic Pathology (2016) 11:37 DOI 10.1186/s13000-016-0486-2 RESEARCH Open Access Diagnostic use of fluorescence in situ hybridization in expert review in a phase 2 study of trabectedin
More informationWhat s New in Colon Cancer? Therapy over the last decade
What s New in Colon Cancer? 9/19/2014 Michael McNamara, MD Therapy over the last decade Cytotoxic chemotherapy - 5FU ( Mayo, Roswell, Infusional) - Xeloda (01 ) - Oxaliplatin (02 ) - Irinotecan (96 ) Anti-
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationMolecular Diagnostics of Bone and Soft Tissue Tumours
Molecular Diagnostics of Bone and Soft Tissue Tumours Judith V.M.G. Bovée Pathologist / Associate professor, Department of Pathology, Leiden University Medical Center, The Netherlands ABSTRACT Bone and
More informationMechanisms of Resistance to Antiangiogenic. Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012
Mechanisms of Resistance to Antiangiogenic Agents Martin J. Edelman, MD University of Maryland Greenebaum Cancer Center Dresden, 2012 Angiogenesis: A fundamental attribute of cancer Premise of Anti-angiogenic
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationEmerging Biomarkers of VEGF and mtor Inhibitors in 2015
Emerging Biomarkers of VEGF and mtor Inhibitors in 2015 Laurence Albiges Institut Gustave Roussy, France Fourteenth International Kidney Cancer Symposium Miami, Florida, USA November 6-7, 2015 www.kidneycancersymposium.com
More informationPhase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 9-12, 2011 Learning Objectives At the end of the session the participant should be able to Define the objectives of screening vs.
More informationNon Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
More informationOff-Label Treatments. Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease. Outline
Off-Label Treatments Clinical Trials for Recurrent GBM UCSF Radiation Oncology Course: Management of Recurrent Disease Jennifer Clarke, MD, MPH Assistant Professor Division of Neuro-Oncology Depts of Neurological
More informationLUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%
More informationNew Agents for Head and Neck Cancer. Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL
New Agents for Head and Neck Cancer Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL Disclosure Dr. Cohen has the following relevant financial relationships with commercial
More informationTiming of targeted therapy in patients with low volume mrcc. Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital
1 Timing of targeted therapy in patients with low volume mrcc Eli Rosenbaum Davidoff Cancer Center Beilinson Hospital 2 Wont be discussing: Symptomatic patients High volume disease Rapidly growing metastases
More information